Beat Helbling
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland
Terziroli Beretta-Piccoli B, Carbone M, Invernizzi P, Baserga A, Oneta C, Filipowicz Sinnreich M, Giostra E, Bihl F, Kalid-de Bakker C, Stickel F, Helbling B, Hessler R, Semela D, Cerny A, Stirnimann G, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clin Rev Allergy Immunol 2017
27.11.2017Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland
27.11.2017Clin Rev Allergy Immunol 2017
Terziroli Beretta-Piccoli Benedetta, Carbone Marco, Invernizzi Pietro, Baserga Adriana, Oneta Carl, Filipowicz Sinnreich Magdalena, Giostra Emiliano, Bihl Florian, Kalid-de Bakker Carolina, Stickel Felix, Helbling Beat, Hessler Roxane, Semela David, Cerny Andreas, Stirnimann Guido, Mertens Joachim
Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1
Stickel F, Worni M, Pache I, Moradpour D, Helbling B, Borovicka J, Gerlach T. Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1. Am J Gastroenterol 2013; 108:1176-8.
01.07.2013Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1
01.07.2013Am J Gastroenterol 2013; 108:1176-8
Stickel Felix, Worni Mathias, Pache Isabelle, Moradpour Darius, Helbling Beat, Borovicka Jan, Gerlach Tilman J
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin
Helbling B, Renner E, Meyer-Wyss B, Esteban A, Mullhaupt B, Dinges S, Wilhelmi M, Gonvers J, Borovicka J, Cerny A, Knöpfli M, Stamenic I, Jochum W, Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. Journal of viral hepatitis 2006; 13:762-9.
01.11.2006HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin
01.11.2006Journal of viral hepatitis 2006; 13:762-9
Helbling Beat, Renner Eberhard L, Meyer-Wyss Beat, Esteban Alicia, Mullhaupt Beat, Dinges Sabine, Wilhelmi Martin, Gonvers Jean-Jacques, Borovicka Jan, Cerny Andreas, Knöpfli Marina, Stamenic Ivan, Jochum Wolfram, Swiss Association for the Study of the Liver (SASL)
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F, Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of hepatology 2005; 42:323-8.
01.03.2005Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
01.03.2005Journal of hepatology 2005; 42:323-8
Broers Barbara, Helbling Beat, François Anne, Schmid Patrick, Chuard Christian, Hadengue Antoine, Negro Francesco, Swiss Association for the Study of the Liver (SASL 18)
Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial
Helbling B, Renner E, Sagmeister M, Borovicka J, Steuerwald M, Cathomas G, Reichen J, Dufour J, Gonvers J, Viani F, Stamenic I, Investigators of the Swiss Association for the Study of the Liver. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology (Baltimore, Md.) 2002; 35:447-54.
01.02.2002Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial
01.02.2002Hepatology (Baltimore, Md.) 2002; 35:447-54
Helbling Beat, Renner Eberhard L, Sagmeister Markus, Borovicka Jan, Steuerwald Michael, Cathomas Gieri, Reichen Jurg, Dufour Jean-François, Gonvers Jean-Jacques, Viani Francesco, Stamenic Ivan, Investigators of the Swiss Association for the Study of the Liver